BCTXW
BriaCell Therapeutics Corp. Warrant
वास्तविक समय मूल्य
मूल्य चार्ट
मुख्य मीट्रिक्स
बाजार मीट्रिक्स
खुलना
$0.000
उच्च
$0.000
कम
$0.000
मात्रा
0.02M
कंपनी के मौलिक सिद्धांत
ट्रेडिंग आँकड़े
संबंधित समाचार
BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26
PHILADELPHIA and VANCOUVER, British Columbia, June 04, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)), (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company
BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025
Three BriaCell posters and one publish-only abstract highlight robust clinical data from Bria-IMT™ and Bria-OTS™ studies in metastatic breast cancer (MBC)Median Overall Survival of 17.3 months in Phase 2
BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor
Bria-OTS has cleared its safety evaluation in the Phase 1/2 study monotherapy dosage settingPhase 1/2 study has now transitioned to dosing patients in combination with checkpoint inhibitor in metastatic breast cancer
BriaCell CEO Letter to Shareholders
Repeated positive recommendation from Data Safety Monitoring Board ("DSMB") of pivotal Phase 3 study for lead clinical candidate Bria-IMT™ in combination with checkpoint inhibitorBria-IMT has received Fast Track
संबंधित स्टॉक
अपडेट रहें
मूल्य अलर्ट सेट करें, AI विश्लेषण अपडेट और वास्तविक समय बाजार समाचार प्राप्त करें।